
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Hldgs is well positioned for success in the biotherapeutics market as it continues to develop and advance its proprietary RaniPill technology. Regulatory risks may impact the timeline of clinical development, but with strong financials and promising early data from its Phase I clinical study for RT-114, the company is poised for potential future growth and partnerships. It will be important to monitor the release of Phase I data and any updates on potential Phase 2 trials for RT-114 in the coming months.
Bears say
Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company that has shown promise with its RaniPill technology, which aims to replace painful injections with oral dosing. However, there is a significant risk of competition from other companies developing similar technologies and a high likelihood of differences in efficacy and safety data as the company's platform advances into multiple dose studies. Management turnover and the need for continued financing also add to the risks for this company. Considering these factors, we believe there is a negative outlook for Rani Therapeutics Hldgs' stock.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares